NasdaqGS:TEMLife Sciences
Tempus AI (TEM) Is Down 6.9% After Raising 2026 Outlook And Filing ESOP Shelf Offering
In February 2026, Tempus AI, Inc. reported full-year 2025 results showing sales of US$955.38 million, revenue of US$1.27 billion, and a net loss of US$245.03 million, alongside new 2026 revenue guidance of about US$1.59 billion and the launch of its HRD-RNA oncology algorithm, while also filing a US$343.38 million Class A common stock shelf registration tied to an ESOP offering.
These updates suggest Tempus AI is pairing rapid top-line expansion and narrowing losses with advancing AI-driven...